Repare Therapeutics Inc Total Liabilities
Repare Therapeutics Inc total liabilities. Based on the latest financial reports, Repare Therapeutics Inc (RPTX) has total liabilities worth $11.62 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Repare Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Repare Therapeutics Inc (2018–2024)
Total liabilities of Repare Therapeutics Inc from 2018 to 2024. This chart illustrates how Repare Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore RPTX long-term investments to assets to see how much of total assets are deployed in long-term investments.
Repare Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Repare Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Changsha Kaiyuan Instruments
SHE:300338
|
China | CN¥485.87 Million |
|
Nava Nakorn Public Company Limited
BK:NNCL
|
Thailand | ฿1.11 Billion |
|
Phu Tai JSC
VN:PTB
|
Vietnam | ₫3.04 Trillion |
|
Dynagas LNG Partners LP
NYSE:DLNG
|
USA | $305.11 Million |
|
Banco Hipotecario SA
BA:BHIP
|
Argentina | AR$3.14 Trillion |
|
Cheffelo AB
ST:CHEF
|
Sweden | Skr325.82 Million |
|
Chernan Metal Industrial
TWO:3631
|
Taiwan | NT$1.04 Billion |
|
Tribeca Global Natural Resources Ltd
AU:TGF
|
Australia | AU$68.42 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Repare Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Repare Therapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Repare Therapeutics Inc Total Liabilities Ratios Explained
Repare Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Repare Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Repare Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Repare Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $25.38 Million | -39.32% |
| 2023-12-31 | $41.82 Million | -50.54% |
| 2022-12-31 | $84.56 Million | +5.31% |
| 2021-12-31 | $80.29 Million | +14.29% |
| 2020-12-31 | $70.26 Million | +447.72% |
| 2019-12-31 | $12.83 Million | -64.67% |
| 2018-12-31 | $36.31 Million | -- |
About Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camo… Read more